Fda Panel Debates Merits Of Next-generation Opioid Formulations

摘要

An FDA advisory panel on November 13-14 examined clinical evidence for a pair of extended-release, abuse-resistant opioid drug products while trying to weigh the needs of patients against the threat of misuse by others.rnRemoxy XRT, an oxycodone product, and Embeda, a morphine-naltrexone formulation, were designed to deter ab users from tampering with the extended-release properties for each drug.rnThe new drug applications were discussed in Gaithersburg, Maryland, at a joint meeting of the FDA's Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.